Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN
Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN
复制标题
DOI：
10.1038/bmt.2010.191
复制
发表时间：
2011-06-01
影响因子：
4.8
通讯作者：
Sugita, K.
中科院分区：
文献类型：
--
作者：
Goi, K.;Inukai, T.;Sugita, K.
尽管自体串联造血SCT改善了晚期高危神经母细胞瘤患者的预后，但结果仍不令人满意。为了诱导移植物抗肿瘤效应，我们在三个连续的具有明显BM浸润和高MYCN扩增的晚期神经母细胞瘤病例中进行了自体PBSCT，然后进行了异基因脐带血移植。所有患者均未发生严重的急性并发症，无病生存37-60个月。这种策略似乎是可行的，有效的治疗极高风险的神经母细胞瘤病例。骨髓移植（2011）46，835-839; doi：10.1038/bmt.2010.191; 2010年8月9日在线发表
Although autologous tandem hematopoietic SCT has improved the prognosis of patients with advanced high-risk neuroblastoma, the results remain unsatisfactory. In an attempt to induce the graft-versus-tumor effect, we performed autologous PBSCT followed by allogeneic cord blood transplantation in three consecutive advanced neuroblastoma cases with marked BM infiltration and high MYCN amplification. Severe acute complications did not occur in any patient and they have maintained disease-free survival for 37-60 months. This strategy appears to be feasible and effective for the treatment of extremely high-risk neuroblastoma cases. Bone Marrow Transplantation (2011) 46, 835-839; doi: 10.1038/bmt.2010.191; published online 9 August 2010